---
title: "CERO THERAPEUTICS HOLDINGS INC C/WTS 13/02/2029 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -61.71"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254229337.md"
datetime: "2025-08-22T20:08:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254229337.md)
  - [en](https://longbridge.com/en/news/254229337.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254229337.md)
---

# CERO THERAPEUTICS HOLDINGS INC C/WTS 13/02/2029 (TO PUR COM) | 10-Q: FY2025 Q2 EPS: USD -61.71

EPS: As of FY2025 Q2, the actual value is USD -61.71.

### Segment Revenue

-   **Research and Development Expenses**: $2,753,963 for the three months ended June 30, 2025, compared to $2,714,344 for the same period in 2024, reflecting an increase of $39,619 or 1.5%.
-   **General and Administrative Expenses**: $1,969,828 for the three months ended June 30, 2025, compared to $2,433,893 for the same period in 2024, reflecting a decrease of $464,065 or 19.1%.

### Operational Metrics

-   **Net Loss**: $5,417,315 for the three months ended June 30, 2025, compared to $2,448,654 for the same period in 2024, reflecting an increase of $2,968,661 or 121.2%.
-   **Total Operating Expenses**: $4,723,791 for the three months ended June 30, 2025, compared to $5,148,237 for the same period in 2024, reflecting a decrease of $424,446 or 8.2%.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $9,068,702 for the six months ended June 30, 2025, compared to - $8,617,285 for the same period in 2024, reflecting an increase in cash used of $451,417.
-   **Net Cash Provided by Financing Activities**: $9,044,316 for the six months ended June 30, 2025, compared to $9,748,916 for the same period in 2024, reflecting a decrease of $704,600.

### Unique Metrics

-   **Deemed Dividend on Series A, B, and C Preferred Stock**: - $24,700,374 for the three months ended June 30, 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to continue its focus on product development, including clinical development, to support regulatory approval and subsequent product commercialization. The company anticipates that its R&D expenses will significantly increase in the future as it increases headcount, compensation expense, and contracted services for preclinical and clinical development of its product candidates.
-   **Non-Core Business**: The company has arranged two equity lines of credit, one providing for the sale of up to 25,000,000 newly issued shares of Common Stock and the other providing for the purchase of up to $17.5 million of Common Stock on the satisfaction of certain conditions.

### Related Stocks

- [CEROW.US](https://longbridge.com/en/quote/CEROW.US.md)

## Related News & Research

- [Meet the Dividend King That's Quietly Crushing the S&P 500 in 2026. Here's Why It's a Buy This August.](https://longbridge.com/en/news/296262501.md)
- [Warren Buffett's Successor, Greg Abel, Has 34.7% of Berkshire Hathaway's Portfolio Invested in These 2 Artificial Intelligence (AI) Stocks](https://longbridge.com/en/news/296274565.md)
- [Oil edges up on uncertainty over exports through Hormuz](https://longbridge.com/en/news/296282399.md)
- [Interactive Brokers Is Holding $930 Billion of Customer Money. Here's What That Earns at Today's Rates.](https://longbridge.com/en/news/296319893.md)
- [ANET, SPOT, HOOD: 3 Best Growth Stocks to Buy This Week, According to Analysts](https://longbridge.com/en/news/296275933.md)